Biotech Values

[DewDiligence]

OCRX—Maybe what BMO was referring to is the lower conditional power, given the demonstrated effect size, being restored back to the unconditional power of 80% with the increase in n.

Maybe, but it’s obvious (and shouldn’t need to be stated) that adding patients raises the conditional power.

Given that some sell-side analysts are not facile with statistics and tend toward pumping, I’m not sure the BMO analyst didn’t mean to imply that that the power of the trial had been increased to more than the 80% it was originally thought to have.